CN101864071A - 聚乙二醇-二硬脂酰磷脂酰乙醇胺衍生物及其制备方法 - Google Patents
聚乙二醇-二硬脂酰磷脂酰乙醇胺衍生物及其制备方法 Download PDFInfo
- Publication number
- CN101864071A CN101864071A CN201010178949A CN201010178949A CN101864071A CN 101864071 A CN101864071 A CN 101864071A CN 201010178949 A CN201010178949 A CN 201010178949A CN 201010178949 A CN201010178949 A CN 201010178949A CN 101864071 A CN101864071 A CN 101864071A
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- preparation
- reaction
- obtains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 25
- 241001597008 Nomeidae Species 0.000 title abstract 3
- -1 Polyethylene Polymers 0.000 title description 6
- 239000004698 Polyethylene Substances 0.000 title 1
- 229920000573 polyethylene Polymers 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 77
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 29
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 24
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 15
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 claims description 13
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 8
- 150000001408 amides Chemical class 0.000 claims description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 claims description 6
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 claims description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 238000010511 deprotection reaction Methods 0.000 claims description 5
- 229960000549 4-dimethylaminophenol Drugs 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 claims description 4
- 238000006555 catalytic reaction Methods 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 claims description 3
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 3
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 claims description 3
- 239000003729 cation exchange resin Substances 0.000 claims description 3
- HCPOCMMGKBZWSJ-UHFFFAOYSA-N ethyl 3-hydrazinyl-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)NN HCPOCMMGKBZWSJ-UHFFFAOYSA-N 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 229930182470 glycoside Natural products 0.000 claims description 3
- 150000002338 glycosides Chemical class 0.000 claims description 3
- 150000002460 imidazoles Chemical class 0.000 claims description 3
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims description 3
- 229960000380 propiolactone Drugs 0.000 claims description 3
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 claims description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 3
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 2
- 239000002841 Lewis acid Substances 0.000 claims description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 229910052796 boron Inorganic materials 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 150000007517 lewis acids Chemical class 0.000 claims description 2
- 235000015320 potassium carbonate Nutrition 0.000 claims description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 2
- 229910052710 silicon Inorganic materials 0.000 claims description 2
- 239000010703 silicon Substances 0.000 claims description 2
- 125000003944 tolyl group Chemical group 0.000 claims description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 2
- 150000003180 prostaglandins Chemical class 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract description 22
- 239000002202 Polyethylene glycol Substances 0.000 abstract description 13
- 206010028980 Neoplasm Diseases 0.000 abstract description 9
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 abstract 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 13
- 238000004440 column chromatography Methods 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 239000012141 concentrate Substances 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 5
- 239000006059 cover glass Substances 0.000 description 5
- 239000002502 liposome Substances 0.000 description 5
- 239000004475 Arginine Substances 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- NTECHUXHORNEGZ-UHFFFAOYSA-N acetyloxymethyl 3',6'-bis(acetyloxymethoxy)-2',7'-bis[3-(acetyloxymethoxy)-3-oxopropyl]-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-carboxylate Chemical compound O1C(=O)C2=CC(C(=O)OCOC(C)=O)=CC=C2C21C1=CC(CCC(=O)OCOC(C)=O)=C(OCOC(C)=O)C=C1OC1=C2C=C(CCC(=O)OCOC(=O)C)C(OCOC(C)=O)=C1 NTECHUXHORNEGZ-UHFFFAOYSA-N 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- HHSARRMUXPDGJD-UHFFFAOYSA-N butyl(dimethyl)silicon Chemical group CCCC[Si](C)C HHSARRMUXPDGJD-UHFFFAOYSA-N 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- SCBJZDPIRGXHFV-JAJWTYFOSA-N 1-[(2S,3R,4S,5S,6R)-2,3,4,5-tetrahydroxy-6-(hydroxymethyl)oxan-2-yl]ethanone Chemical compound C(C)(=O)[C@]1(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO SCBJZDPIRGXHFV-JAJWTYFOSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000001189 Cyclic Peptides Human genes 0.000 description 2
- 108010069514 Cyclic Peptides Proteins 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- CFHIDWOYWUOIHU-UHFFFAOYSA-N oxomethyl Chemical compound O=[CH] CFHIDWOYWUOIHU-UHFFFAOYSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- 125000006278 bromobenzyl group Chemical group 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- SIHHLZPXQLFPMC-UHFFFAOYSA-N chloroform;methanol;hydrate Chemical compound O.OC.ClC(Cl)Cl SIHHLZPXQLFPMC-UHFFFAOYSA-N 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940115080 doxil Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Polyethers (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101789492A CN101864071B (zh) | 2010-05-21 | 2010-05-21 | 聚乙二醇-二硬脂酰磷脂酰乙醇胺衍生物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010101789492A CN101864071B (zh) | 2010-05-21 | 2010-05-21 | 聚乙二醇-二硬脂酰磷脂酰乙醇胺衍生物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101864071A true CN101864071A (zh) | 2010-10-20 |
CN101864071B CN101864071B (zh) | 2011-12-21 |
Family
ID=42956019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010101789492A Active CN101864071B (zh) | 2010-05-21 | 2010-05-21 | 聚乙二醇-二硬脂酰磷脂酰乙醇胺衍生物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101864071B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103360590A (zh) * | 2012-04-12 | 2013-10-23 | 南京康海磷脂生物技术有限公司 | 一种甲氧基聚乙二醇-二脂肪酰磷脂酰乙醇胺的制备方法 |
CN110237268A (zh) * | 2019-07-18 | 2019-09-17 | 南方医科大学南方医院 | 一种载有阿霉素的双响应脂质体微泡复合物的制备方法 |
CN114989415A (zh) * | 2022-08-04 | 2022-09-02 | 北京鑫开元医药科技有限公司 | 主动靶向性磷脂及其合成工艺 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003101425A2 (en) * | 2002-06-03 | 2003-12-11 | Alnis Biosciences, Inc. | Therapeutic agent-containing polymeric nanoarticles |
CN1846691A (zh) * | 2005-04-11 | 2006-10-18 | 北京大学 | 注射用的整合素配体修饰的载抗癌药的长循环脂质体 |
CN101327190A (zh) * | 2008-07-29 | 2008-12-24 | 北京大学 | 一种供注射用的抗肿瘤长循环靶向脂质体 |
WO2009123768A2 (en) * | 2008-04-04 | 2009-10-08 | Rutgers University | Nanocarrier and nanogel compositions |
-
2010
- 2010-05-21 CN CN2010101789492A patent/CN101864071B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003101425A2 (en) * | 2002-06-03 | 2003-12-11 | Alnis Biosciences, Inc. | Therapeutic agent-containing polymeric nanoarticles |
CN1846691A (zh) * | 2005-04-11 | 2006-10-18 | 北京大学 | 注射用的整合素配体修饰的载抗癌药的长循环脂质体 |
WO2009123768A2 (en) * | 2008-04-04 | 2009-10-08 | Rutgers University | Nanocarrier and nanogel compositions |
CN101327190A (zh) * | 2008-07-29 | 2008-12-24 | 北京大学 | 一种供注射用的抗肿瘤长循环靶向脂质体 |
Non-Patent Citations (1)
Title |
---|
《药学学报》 20051228 熊小兵等 "RGD类似物修饰的阿霉素隐形脂质体的制备及体外细胞结合试验" 1085-1090 1-10 第40卷, 第12期 2 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103360590A (zh) * | 2012-04-12 | 2013-10-23 | 南京康海磷脂生物技术有限公司 | 一种甲氧基聚乙二醇-二脂肪酰磷脂酰乙醇胺的制备方法 |
CN103360590B (zh) * | 2012-04-12 | 2015-02-18 | 南京康海磷脂生物技术有限公司 | 一种甲氧基聚乙二醇-二脂肪酰磷脂酰乙醇胺的制备方法 |
CN110237268A (zh) * | 2019-07-18 | 2019-09-17 | 南方医科大学南方医院 | 一种载有阿霉素的双响应脂质体微泡复合物的制备方法 |
CN110237268B (zh) * | 2019-07-18 | 2023-02-03 | 南方医科大学南方医院 | 一种载有阿霉素的双响应脂质体微泡复合物的制备方法 |
CN114989415A (zh) * | 2022-08-04 | 2022-09-02 | 北京鑫开元医药科技有限公司 | 主动靶向性磷脂及其合成工艺 |
CN114989415B (zh) * | 2022-08-04 | 2022-10-21 | 北京鑫开元医药科技有限公司 | 主动靶向性磷脂及其合成工艺 |
Also Published As
Publication number | Publication date |
---|---|
CN101864071B (zh) | 2011-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5880131A (en) | High molecular weight polymer-based prodrugs | |
US5614549A (en) | High molecular weight polymer-based prodrugs | |
Pu et al. | Dual-targeting liposomes with active recognition of GLUT5 and αvβ3 for triple-negative breast cancer | |
US5965566A (en) | High molecular weight polymer-based prodrugs | |
AU659750B2 (en) | Polymer-bound paclitaxel derivatives | |
WO2021208459A1 (zh) | 免疫激动剂 | |
CN101864071B (zh) | 聚乙二醇-二硬脂酰磷脂酰乙醇胺衍生物及其制备方法 | |
Danieli et al. | Thiocolchicine− podophyllotoxin conjugates: dynamic libraries based on disulfide exchange reaction | |
Oumzil et al. | Reduction-triggered delivery using nucleoside-lipid based carriers possessing a cleavable PEG coating | |
CN110433292B (zh) | 一种双靶向材料及其在药物传递中的应用 | |
KR20100119491A (ko) | 올리고카르보네이트 분자 수송체 | |
CN102898641A (zh) | 一种含单一活性官能团的y型聚乙二醇及其制备方法 | |
KR20220038601A (ko) | 캄토테신 약물 및 그의 항체 접합체 | |
CA3226268A1 (en) | M6pr cell surface receptor binding compounds and conjugates | |
CN105396141B (zh) | iRGD-抗癌药物偶联物及其制备方法和应用 | |
Liang et al. | Novel polymeric micelles with cinnamic acid as lipophilic moiety for 9-Nitro-20 (S)-camptothecin delivery | |
Xiao et al. | Development of bifunctional anti-PD-L1 antibody MMAE conjugate with cytotoxicity and immunostimulation | |
EP3466415A1 (en) | Polymer ca4 bonding pharmaceutical compound and preparation method therefor | |
CN106146824A (zh) | 利用天然糖抗体靶向免疫治疗肿瘤的脂质体及其制备方法 | |
Yu et al. | Synthesis and characterization of arginine–glycine–aspartic peptides conjugated poly (lactic acid-co-l-lysine) diblock copolymer | |
JP6276274B2 (ja) | 生物活性物質の送達のための低分子量分岐ポリアミン | |
JP7051906B2 (ja) | ペクチン-ドキソルビシン共役化合物及びその調製方法と用途 | |
CN110917139A (zh) | 多分枝生物素修饰的乳腺癌靶向脂质体的制备和应用 | |
CN110522923A (zh) | 果糖和rgd肽共修饰的双重靶向三阴性乳腺癌的脂质材料 | |
EP3162367A1 (en) | Composition for skin penetration, containing cationic molecule transporter and anionic bioactive material |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Polyethylene glycol-distearoyl phosphatidyl ethanolamine derivant and preparation method thereof Effective date of registration: 20191125 Granted publication date: 20111221 Pledgee: Shenyang Shengjing Financing Guarantee Co.,Ltd. Pledgor: Beijing Zhonghaikang Pharmaceutical Technology Development Co.,Ltd. Registration number: Y2019210000016 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20201201 Granted publication date: 20111221 Pledgee: Shenyang Shengjing Financing Guarantee Co.,Ltd. Pledgor: BEIJING ZHONGHAIKANG PHARMACEUTICAL TECHNOLOGY DEVELOPMENT Co.,Ltd. Registration number: Y2019210000016 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Polyethylene glycol Distearyl phosphatidylethanolamine derivative and its preparation method Effective date of registration: 20201202 Granted publication date: 20111221 Pledgee: Shenyang Shengjing Financing Guarantee Co.,Ltd. Pledgor: BEIJING ZHONGHAIKANG PHARMACEUTICAL TECHNOLOGY DEVELOPMENT Co.,Ltd. Registration number: Y2020210000066 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20211011 Granted publication date: 20111221 Pledgee: Shenyang Shengjing Financing Guarantee Co.,Ltd. Pledgor: BEIJING ZHONGHAIKANG PHARMACEUTICAL TECHNOLOGY DEVELOPMENT Co.,Ltd. Registration number: Y2020210000066 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Beijing Zhonghaikang Pharmaceutical Technology Development Co.,Ltd. Person in charge of patents Document name: payment instructions |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Beijing Zhonghaikang Pharmaceutical Technology Development Co.,Ltd. Person in charge of patents Document name: Notice of Termination of Patent Rights |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Beijing Zhonghaikang Pharmaceutical Technology Development Co.,Ltd. Person in charge of patents Document name: Notice of Completing the Procedures for Restoring Rights |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Beijing Zhonghaikang Pharmaceutical Technology Development Co.,Ltd. Person in charge of patents Document name: Notice of Approval for Request for Restoration of Rights |